Creative Planning
PGNX

Creative Planning’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Creative Planning’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,900
Closed -$101K – 2150
2019
Q3 		$101K Hold
19,900
– – ﹤0.01% 1716
2019
Q2 		$123K Buy
19,900
+2,000
+11% +$9.64K ﹤0.01% 1722
2019
Q1 		$83K Hold
17,900
– – ﹤0.01% 1726
2018
Q4 		$75K Sell
17,900
-240,700
-93% -$1.23M ﹤0.01% 1667
2018
Q3 		$1.62M Buy
258,600
+49,890
+24% +$383K 0.01% 545
2018
Q2 		$1.68M Buy
208,710
+50,310
+32% +$384K 0.01% 523
2018
Q1 		$1.18M Buy
158,400
+16,600
+12% +$110K ﹤0.01% 651
2017
Q4 		$844K Buy
141,800
+38,400
+37% +$233K ﹤0.01% 820
2017
Q3 		$761K Buy
103,400
+100,500
+3,466% +$638K ﹤0.01% 835
2017
Q2 		$20K Sell
2,900
-9,350
-76% -$69K ﹤0.01% 3198
2017
Q1 		$116K Sell
12,250
-2,950
-19% -$29.4K ﹤0.01% 1856
2016
Q4 		$131K Sell
15,200
-57,800
-79% -$427K ﹤0.01% 1684
2016
Q3 		$462K Buy
73,000
+70,000
+2,333% +$423K ﹤0.01% 934
2016
Q2 		$13K Hold
3,000
– – ﹤0.01% 3099
2016
Q1 		$13K Sell
3,000
-200
-6% -$891 ﹤0.01% 3074
2015
Q4 		$20K Buy
+3,200
New +$21K ﹤0.01% 2862
2014
Q3 		– Sell
-1,500
Closed -$6K – 4222
2014
Q2 		$6K Hold
1,500
– – ﹤0.01% 3151
2014
Q1 		$6K Buy
+1,500
New +$7.67K ﹤0.01% 3026

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Creative Planning's PGNX Position: Q4 2019 in Review

Creative Planning sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 19,900 shares — an estimated $101K sold.

Creative Planning first reported a position in PGNX in Q1 2014 and held it in 18 quarters. The position peaked at $1.68M in Q2 2018. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Creative Planning reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Creative Planning sold 19,900 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $101K.
  • Creative Planning first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 18 quarters.
  • Creative Planning's Progenics Pharmaceuticals Inc position peaked at $1.68M in Q2 2018.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Creative Planning's 13F filing for Q4 2019, filed 30 Jan 2020.